MedtronicMDT
MDT
About: One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
Employees: 95,000
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
49% more first-time investments, than exits
New positions opened: 226 | Existing positions closed: 152
2% more funds holding
Funds holding: 2,037 [Q3] → 2,073 (+36) [Q4]
1.7% more ownership
Funds ownership: 81.28% [Q3] → 82.97% (+1.7%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 31 [Q3] → 31 (+0) [Q4]
7% less call options, than puts
Call options by funds: $586M | Put options by funds: $632M
11% less capital invested
Capital invested by funds: $95.9B [Q3] → $85B (-$10.8B) [Q4]
12% less repeat investments, than reductions
Existing positions increased: 773 | Existing positions reduced: 875
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$91
4%
upside
Avg. target
$100
14%
upside
High target
$107
22%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
Citigroup Joanne Wuensch 43% 1-year accuracy 22 / 51 met price target | 22%upside $107 | Buy Upgraded | 4 Mar 2025 |
RBC Capital Shagun Singh 60% 1-year accuracy 40 / 67 met price target | 20%upside $105 | Outperform Reiterated | 19 Feb 2025 |
UBS Danielle Antalffy 38% 1-year accuracy 5 / 13 met price target | 8%upside $95 | Neutral Maintained | 19 Feb 2025 |
Baird David Rescott 75% 1-year accuracy 12 / 16 met price target | 4%upside $91 | Neutral Maintained | 19 Feb 2025 |
Financial journalist opinion
Based on 23 articles about MDT published over the past 30 days
Neutral
PRNewsWire
10 hours ago
Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients
GALWAY, Ireland and CHICAGO , March 30, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes.
Positive
The Motley Fool
2 days ago
Prediction: Buying Medtronic Today Will Set You Up for Life
Healthcare can be a complex sector, and it is one that I long ago decided to outsource to the industry professionals who run closed-end fund Blackrock Health Sciences Trust. But I couldn't resist dipping my toe into the sector when I saw the historically high yield on offer from Medtronic (MDT 0.88%), one of the largest and most diversified medical device makers.
Negative
Zacks Investment Research
3 days ago
Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know
Medtronic (MDT) concluded the recent trading session at $88.98, signifying a +0.85% move from its prior day's close.
Negative
Investors Business Daily
3 days ago
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a "wait-and-see" pattern.
Neutral
The Motley Fool
3 days ago
2 Recession-Proof Dividend Stocks to Buy and Hold
Fears of a looming recession seem to be rising, partly fueled by President Donald Trump's macroeconomic policies. While it's impossible to predict whether an economic downturn is indeed coming, it's not a bad idea for investors to purchase shares of companies that are likely to perform relatively well in case it does happen.
Neutral
Zacks Investment Research
5 days ago
Does the S&P 500 Rally Make MDT Stock a Buy Amid Easing Trade Tension?
Medtronic's Hypertension business is on the brink of a major expansion, driven by its Simplicity blood pressure procedure.
Positive
Zacks Investment Research
6 days ago
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.
Positive
Zacks Investment Research
1 week ago
Investors Heavily Search Medtronic PLC (MDT): Here is What You Need to Know
Medtronic (MDT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Positive
Zacks Investment Research
1 week ago
Medtronic (MDT) Up 5.6% Since Last Earnings Report: Can It Continue?
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?
Positive
Seeking Alpha
1 week ago
Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy
Upgraded Medtronic to a ‘Buy' rating with a fair value of $105 per share, driven by strong growth in Cardiac Ablation Solutions and TAVR markets. Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth, highlighting significant momentum in its Cardiac Ablation Solutions business. The company's structural heart business, especially the Evolut FX+ TAVR system, is showing strong adoption and competitive advantages over Edwards Lifesciences's SAPIEN TAVR product.
Charts implemented using Lightweight Charts™